BOSTON, Oct. 14, 2020 /PRNewswire/ — Orbita, the leading provider of HIPAA-compliant conversational voice and chat solutions for healthcare and life science organizations, today launched a new module designed to help pharmaceutical companies better detect and report adverse events. The new platform-agnostic Adverse Event module, built on the latest technology in machine learning and natural language processing, integrates into existing chat services to accurately detect and seamlessly assist users in reporting adverse reactions to medications, ultimately improving the efficiency and timeliness of adverse event reporting.
Machine learning fuels seamless and accurate reporting
Chatbots are an increasingly popular tool for patient support programs, but few are equipped to accurately flag if a patient is having a medication-induced side effect, which can hinder pharmacovigilance processes and success. Orbita’s new Adverse Event module draws from a robust corpus of medical and conversational data, while machine learning continually improves the module to increase
Electrical engineers, computer scientists and biomedical engineers at the University of California, Irvine have created a new lab-on-a-chip that can help study tumor heterogeneity to reduce resistance to cancer therapies.
In a paper published today in Advanced Biosystems, the researchers describe how they combined artificial intelligence, microfluidics and nanoparticle inkjet printing in a device that enables the examination and differentiation of cancers and healthy tissues at the single-cell level.
“Cancer cell and tumor heterogeneity can lead to increased therapeutic resistance and inconsistent outcomes for different patients,” said lead author Kushal Joshi, a former UCI graduate student in biomedical engineering. The team’s novel biochip addresses this problem by allowing precise characterization of a variety of cancer cells from a sample.
“Single-cell analysis is essential to identify and classify cancer types and study cellular heterogeneity. It’s necessary to understand tumor initiation, progression and metastasis in order to design better cancer treatment
A new IIASA-led study shows that coordinated international action on energy-efficient, climate-friendly cooling could avoid as much as 600 billion tons CO2 equivalent of greenhouse gas emissions in this century.
Hydrofluorocarbons (HFCs) are mainly used for cooling and refrigeration. While they were originally developed to replace ozone-depleting substances that are being phased out under the Montreal Protocol, many HFCs are potent greenhouse gases with a global warming potential up to 12,400 times that of CO2 over a 100-year period.
The Kigali Amendment to the Montreal Protocol, which entered into force in 2019, aims to phase down the consumption of HFCs by 2050. While previous agreements have resulted in improvements in the design and energy performance of, for instance, cooling equipment, the Kigali Amendment is the first to include maintaining and/or enhancing the energy efficiency of cooling technologies as an explicit goal. According to the
South Africa and India have asked the World Trade Organization to waive some provisions in the international agreements that regulate intellectual property rights to speed up efforts to prevent, treat and contain the COVID-19 pandemic
ANIRUDDHA GHOSAL and CARA ANNA Associated Press
October 3, 2020, 10:42 AM
• 4 min read
NEW DELHI — South Africa and India have asked the World Trade Organization to waive some provisions in the international agreements that regulate intellectual property rights, to speed up efforts to prevent, treat and contain the COVID-19 pandemic and make sure developing countries are not left behind.
The countries argue, in a joint submission to the Council for Trade-Related Aspects of Intellectual Property Rights dated Friday, that without a rapid waiver of some existing safeguards for intellectual property rights, some countries — particularly developing ones that have been “disproportionately